ResMed (NYSE:RMD) Given New $288.00 Price Target at Royal Bank Of Canada

ResMed (NYSE:RMD) had its price objective raised by Royal Bank Of Canada from $262.00 to $288.00 in a report issued on Friday morning,Benzinga reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

Other analysts also recently issued reports about the company. Citigroup reissued a “neutral” rating on shares of ResMed in a research note on Thursday, September 10th. Rothschild & Co Redburn initiated coverage on ResMed in a research report on Wednesday, August 19th. They issued a “neutral” rating and a $230.00 price target for the company. Jefferies Financial Group dropped their price objective on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Friday. Finally, Robert W. Baird set a $213.00 target price on shares of ResMed in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $253.69.

ResMed Price Performance

Shares of RMD opened at $230.76 on Friday. ResMed has a 12-month low of $180.26 and a 12-month high of $277.67. The business’s fifty day moving average is $231.87 and its 200 day moving average is $225.43. The company has a quick ratio of 2.42, a current ratio of 3.10 and a debt-to-equity ratio of 0.06. The stock has a market cap of $32.45 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.55 and a beta of 0.75.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 25.90%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm earned $2.55 earnings per share. Sell-side analysts anticipate that ResMed will post 12.11 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 12th. ResMed’s dividend payout ratio (DPR) is 25.31%.

Insider Buying and Selling

In other ResMed news, CEO Michael Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $205.69, for a total transaction of $1,026,598.79. Following the completion of the sale, the chief executive officer directly owned 466,256 shares in the company, valued at $95,904,196.64. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of the firm’s stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total transaction of $102,000.00. Following the sale, the general counsel owned 12,318 shares in the company, valued at approximately $3,141,090. This trade represents a 3.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 24,343 shares of company stock worth $5,396,098. Insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in ResMed in the 2nd quarter worth $2,400,375,000. Bank of New York Mellon Corp purchased a new stake in ResMed during the 2nd quarter valued at about $818,030,000. Deutsche Bank AG purchased a new stake in ResMed during the 2nd quarter valued at about $257,692,000. Legal & General Group Plc bought a new position in ResMed during the 2nd quarter worth approximately $183,697,000. Finally, Bank of America Corp DE purchased a new position in ResMed in the 2nd quarter worth approximately $151,115,000. 54.98% of the stock is currently owned by institutional investors.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share versus the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, ahead of the $1.39 billion forecast. ResMed fiscal first-quarter results
• Positive Sentiment: Profitability and demand trends improved. Sustained demand for sleep devices, productivity gains and gross-margin expansion supported the earnings beat. EPS increased from $2.55 in the year-ago quarter, and ResMed reported a 26.94% net margin. ResMed earnings and margin growth
• Positive Sentiment: Analysts raised price targets. RBC increased its target from $262 to $288 and assigned an “outperform” rating. KeyCorp raised its target from $267 to $277 with an “overweight” rating, while Wells Fargo lifted its target from $215 to $250 and maintained “equal weight.” Citigroup raised its target from $240 to $270 but retained a “neutral” rating. Analyst target changes
• Neutral Sentiment: ResMed declared a quarterly dividend of $0.66 per share, or $2.64 annualized, representing an approximately 1.1% yield. The dividend supports shareholder returns but is unlikely to be the primary near-term stock catalyst.
• Negative Sentiment: Full-year guidance was unchanged. The lack of an outlook increase may have disappointed investors who expected the earnings beat and improving margins to result in raised expectations. The neutral ratings from Citigroup and Wells Fargo may also limit the impact of the higher price targets. ResMed maintains prior guidance

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.